Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

A Registry for Participants With Chronic Hypoparathyroidism

NCT01922440 · View on ClinicalTrials.gov ↗

Study Summary

The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH\[1-84\]) treatment in participants with chronic hypoparathyroidism under conditions of routine clinical practice. Participants will be treated according to their clinic's standard practice determined by the treating doctors. Each participant will fill out a study questionnaire during a routine doctor visit.

Conditions Studied

Interventions

  • OTHER No intervention

Study Locations (20)

Illinois

  • Suburban Endocrinology & Diabetes — Arlington Heights
  • University of Chicago Medical Center — Chicago
  • Northshore University Health System — Evanston
  • Loyola University Medical Center — Maywood

California

  • Children's Hospital Los Angeles — Los Angeles
  • Cedars-Sinai Medical Center — Los Angeles
  • Dr. Joselito Cabaccan — San Jose

Florida

  • Hanson Clinical Research Center — Port Charlotte
  • Thyroid & Endocrine Center of Florida — Sarasota

Maryland

  • Model Clinical Research — Baltimore
  • Medstar Union Memorial Hospital — Baltimore

Massachusetts

  • Massachusetts General Hospital — Boston
  • Brigham and Women's Hospital — Boston

Alabama

  • University of Alabama at Birmingham — Birmingham

Arizona

  • University of Arizona Medical Center — Tucson

Colorado

  • University of Colorado Hospital — Aurora

Trial Details

FieldValue
Enrollment Target 1,339 participants
Start Date 2013-07-30
Est. Completion 2034-11-30

Sponsor

Takeda

387 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01922440

The ClinicalTrials.gov registry entry for NCT01922440 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,339 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 387 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Hypoparathyroidism appearing as the primary indexed condition, and to 1 intervention — of which No intervention is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01922440 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Illinois, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01922440 about?

NCT01922440 is a clinical study titled "A Registry for Participants With Chronic Hypoparathyroidism". The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH\[1-84\]) treatment in participants with chronic hypoparathyroidism under conditions of routine clinical practice. Participants will be treated according to...

What is the current status of trial NCT01922440?

This trial is currently active not recruiting. The enrollment target is 1,339 participants. The study started on 2013-07-30. Estimated completion is 2034-11-30.

What conditions does trial NCT01922440 study?

This clinical trial studies the following conditions: Hypoparathyroidism. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01922440?

The interventions under investigation include: No intervention (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01922440?

This trial is sponsored by Takeda, which has 387 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01922440 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial